Biomerica
Market Cap
US$30.6m
Last Updated
2019/09/20 00:09 UTC
Data Sources
Company Financials +
Executive Summary
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions.
Snowflake
Fundamentals
High growth potential with adequate balance sheet.
Risks
- Biomerica has significant price volatility in the past 3 months.
- Biomerica is covered by less than 3 analysts.
Similar Companies
Share Price & News
How has Biomerica's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.0%
BMRA
0.7%
US Medical Equipment
-0.2%
US Market
1 Year Return
-10.6%
BMRA
9.5%
US Medical Equipment
1.1%
US Market
BMRA underperformed the Medical Equipment industry which returned 9.9% over the past year.
BMRA underperformed the Market in United States of America which returned 1.6% over the past year.
Share holder returns
| BMRA | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.0% | 0.7% | -0.2% |
| 30 Day | 7.9% | 0.1% | 2.5% |
| 90 Day | 32.6% | 2.5% | 1.6% |
| 1 Year | -10.6%-10.6% | 10.4%9.5% | 3.4%1.1% |
| 3 Year | 13.4%13.4% | 69.3%64.1% | 45.2%35.8% |
| 5 Year | 255.7%255.7% | 138.0%110.9% | 62.6%44.8% |
Price Volatility Vs. Market
How volatile is Biomerica's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
How Does Investing In Biomerica, Inc. (NASDAQ:BMRA) Impact The Volatility Of Your Portfolio?4 weeks ago | Simply Wall St
How Much is Biomerica, Inc.'s (NASDAQ:BMRA) CEO Getting Paid?1 month ago | Simply Wall St
Do Directors Own Biomerica, Inc. (NASDAQ:BMRA) Shares?Valuation
Is Biomerica undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Biomerica's share price is below the future cash flow value, and at a moderate discount (> 20%).
Biomerica's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Biomerica is loss making, we can't compare its value to the US Medical Equipment industry average.
Biomerica is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Biomerica, we can't assess if its growth is good value.
Price Based on Value of Assets
Biomerica is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Biomerica expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
69.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Biomerica's revenue is expected to grow significantly at over 20% yearly.
Biomerica's earnings are expected to grow significantly at over 20% yearly.
Biomerica's revenue growth is expected to exceed the United States of America market average.
Biomerica's earnings growth is expected to exceed the United States of America market average.
Biomerica's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Biomerica will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Biomerica performed over the past 5 years?
-39.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Biomerica does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Biomerica's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Biomerica's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Biomerica has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Biomerica has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Biomerica improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Biomerica's financial position?
Financial Position Analysis
Biomerica is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Biomerica has no long term commitments.
Debt to Equity History and Analysis
Biomerica has no debt.
Biomerica has not taken on any debt in the past 5 years.
Balance Sheet
High level of physical assets or inventory.
Biomerica has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Biomerica has less than a year of cash runway based on current free cash flow.
Biomerica has less than a year of cash runway if free cash flow continues to grow at historical rates of 66% each year.
Next Steps
Dividend
What is Biomerica's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Biomerica's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Biomerica's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Biomerica has not reported any payouts.
Unable to verify if Biomerica's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Biomerica has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Biomerica's salary, the management and board of directors tenure and is there insider trading?
16.2yrs
Average board tenure
CEO
Zackary Irani (53yo)
22.4yrs
Tenure
US$295,081
Compensation
Mr. Zackary S. Irani has been Chairman of the Board and Chief Executive Officer of Biomerica Inc. since April 29, 1997 and served as its President. Mr. Irani serves as the President and Chairman of ReadySc ...
CEO Compensation Analysis
Zackary's remuneration is lower than average for companies of similar size in United States of America.
Zackary's compensation has increased whilst company is loss making.
Board Age and Tenure
16.2yrs
Average Tenure
65yo
Average Age
The average tenure for the Biomerica board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Janet Moore (68yo)
CFO, Treasurer
- Tenure: 22.4yrs
- Compensation: US$166.43k
Zackary Irani (53yo)
Chairman & CEO
- Tenure: 22.4yrs
- Compensation: US$295.08k
Board Members
Ned Barnholt (75yo)
Chairman of Strategic Advisory Board
- Tenure: 0yrs
Janet Moore (68yo)
CFO, Treasurer
- Tenure: 22.4yrs
- Compensation: US$166.43k
Zackary Irani (53yo)
Chairman & CEO
- Tenure: 22.4yrs
- Compensation: US$295.08k
Francis Cano (72yo)
Director
- Tenure: 20.3yrs
- Compensation: US$50.29k
Mark Sirgo (65yo)
Director
- Tenure: 3.2yrs
- Compensation: US$50.29k
Allen Barbieri (61yo)
Director
- Tenure: 19.9yrs
- Compensation: US$50.29k
Harry Leider
Member of Strategic Advisory Board
- Tenure: 1.4yrs
Jane Emerson (65yo)
Director
- Tenure: 12.4yrs
- Compensation: US$60.29k
Tony Lembo
Member of Scientific Advisory Board
- Tenure: 3.2yrs
Company Information
Biomerica, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biomerica, Inc.
- Ticker: BMRA
- Exchange: NasdaqCM
- Founded: 1971
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$30.576m
- Shares outstanding: 9.77m
- Website: https://www.biomerica.com
Number of Employees
Location
- Biomerica, Inc.
- 17571 Von Karman Avenue
- Irvine
- California
- 92614
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BMRA | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jan 1975 |
Biography
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The compa ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/20 00:09 |
| End of Day Share Price | 2019/09/19 00:00 |
| Earnings | 2019/05/31 |
| Annual Earnings | 2019/05/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.